Men experiencing baldness by age 30 may have a significantly reduced risk of developing prostate cancer. Research indicates that individuals who began losing hair by this age had a 29% lower risk of the disease, with those experiencing even earlier onset baldness showing a 45% reduced risk for both aggressive and less-aggressive forms.
While the precise cause for this correlation remains unclear, researchers hypothesize that a shared genetic variant within the male hormone receptor gene may influence both hair loss and prostate cancer susceptibility. Dihydrotestosterone, a hormone derived from testosterone, is a known factor in male pattern baldness, hindering nutrient absorption by hair follicles. Testosterone also plays a role in the growth of prostate cancer cells, suggesting a potential link through androgen pathways.
"Early onset baldness may be a more relevant measure considering the long latency of prostate cancer and the presumed related effects of the androgen pathway in these conditions," stated study lead Dr. Jonathan Wright in a press release.
This finding contrasts with some earlier research. A 2016 study, for instance, found an association between male pattern hair loss and death from prostate cancer, reporting a 56% higher risk of fatal prostate cancer for any baldness between ages 25 and 44, and an 83% higher risk for moderate balding.
Prostate cancer is the most common cancer among men and the second-leading cause of cancer-related death in males. Early-stage prostate cancer often presents no symptoms because the tumors are small. Potential indicators include difficulty urinating, which can result from an enlarged prostate pressing on the bladder and urethra. When the cancer spreads, it commonly metastasizes to the bones, potentially causing pain and neurological issues.
The exact causes of prostate cancer are not fully understood, but a genetic predisposition is recognized, similar to male pattern baldness. Current screening recommendations generally advise for screening between ages 55 and 69, with individuals at increased risk advised to begin screening at age 40.